A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 3018250 in Patients With Symptomatic Proximal Deep Vein Thrombosis
Latest Information Update: 23 Feb 2025
At a glance
- Drugs BAY 3018250 (Primary)
- Indications Deep vein thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIRIUS
- Sponsors Bayer
- 22 Jan 2025 Planned End Date changed from 2 Oct 2025 to 6 Oct 2025.
- 22 Jan 2025 Planned primary completion date changed from 2 Aug 2025 to 5 Aug 2025.
- 20 Jun 2024 Planned End Date changed from 3 Jul 2025 to 2 Oct 2025.